NASDAQ:AMTI

Applied Molecular Transport Competitors

$41.93
+1.58 (+3.92 %)
(As of 04/16/2021 11:03 AM ET)
Add
Compare
Today's Range
$40.38
Now: $41.93
$43.13
50-Day Range
$40.67
MA: $57.24
$74.14
52-Week Range
$17.05
Now: $41.93
$78.22
Volume2,096 shs
Average Volume220,933 shs
Market Capitalization$1.48 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Applied Molecular Transport (NASDAQ:AMTI) Vs. BPMC, PRGO, SDGR, GLPG, BHVN, and SAGE

Should you be buying AMTI stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Applied Molecular Transport, including Blueprint Medicines (BPMC), Perrigo (PRGO), Schrödinger (SDGR), Galapagos (GLPG), Biohaven Pharmaceutical (BHVN), and Sage Therapeutics (SAGE).

Blueprint Medicines (NASDAQ:BPMC) and Applied Molecular Transport (NASDAQ:AMTI) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Analyst Recommendations

This is a summary of current recommendations and price targets for Blueprint Medicines and Applied Molecular Transport, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Blueprint Medicines06812.67
Applied Molecular Transport00403.00

Blueprint Medicines currently has a consensus price target of $112.40, indicating a potential upside of 17.14%. Applied Molecular Transport has a consensus price target of $68.75, indicating a potential upside of 63.96%. Given Applied Molecular Transport's stronger consensus rating and higher probable upside, analysts plainly believe Applied Molecular Transport is more favorable than Blueprint Medicines.

Insider & Institutional Ownership

52.0% of Applied Molecular Transport shares are owned by institutional investors. 3.8% of Blueprint Medicines shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Blueprint Medicines and Applied Molecular Transport's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Blueprint Medicines$66.51 million83.61$-347,690,000.00($7.27)-13.20
Applied Molecular TransportN/AN/A$-28,040,000.00N/AN/A

Applied Molecular Transport has lower revenue, but higher earnings than Blueprint Medicines.

Profitability

This table compares Blueprint Medicines and Applied Molecular Transport's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Blueprint Medicines41.08%43.72%33.35%
Applied Molecular TransportN/AN/AN/A

Summary

Blueprint Medicines beats Applied Molecular Transport on 7 of the 11 factors compared between the two stocks.

Applied Molecular Transport (NASDAQ:AMTI) and Perrigo (NYSE:PRGO) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends.

Analyst Recommendations

This is a summary of recent ratings and price targets for Applied Molecular Transport and Perrigo, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Applied Molecular Transport00403.00
Perrigo04102.20

Applied Molecular Transport currently has a consensus price target of $68.75, indicating a potential upside of 63.96%. Perrigo has a consensus price target of $52.00, indicating a potential upside of 25.36%. Given Applied Molecular Transport's stronger consensus rating and higher possible upside, analysts plainly believe Applied Molecular Transport is more favorable than Perrigo.

Institutional and Insider Ownership

52.0% of Applied Molecular Transport shares are owned by institutional investors. Comparatively, 82.7% of Perrigo shares are owned by institutional investors. 0.3% of Perrigo shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Applied Molecular Transport and Perrigo's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Applied Molecular TransportN/AN/AN/A
Perrigo-0.13%9.78%4.92%

Earnings and Valuation

This table compares Applied Molecular Transport and Perrigo's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Applied Molecular TransportN/AN/A$-28,040,000.00N/AN/A
Perrigo$4.84 billion1.15$146.10 million$4.0310.29

Perrigo has higher revenue and earnings than Applied Molecular Transport.

Summary

Perrigo beats Applied Molecular Transport on 6 of the 10 factors compared between the two stocks.

Schrödinger (NASDAQ:SDGR) and Applied Molecular Transport (NASDAQ:AMTI) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, institutional ownership and valuation.

Institutional & Insider Ownership

41.3% of Schrödinger shares are held by institutional investors. Comparatively, 52.0% of Applied Molecular Transport shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Schrödinger and Applied Molecular Transport, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Schrödinger01302.75
Applied Molecular Transport00403.00

Schrödinger currently has a consensus target price of $85.50, suggesting a potential upside of 9.36%. Applied Molecular Transport has a consensus target price of $68.75, suggesting a potential upside of 63.96%. Given Applied Molecular Transport's stronger consensus rating and higher possible upside, analysts clearly believe Applied Molecular Transport is more favorable than Schrödinger.

Profitability

This table compares Schrödinger and Applied Molecular Transport's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Schrödinger-19.92%-7.25%-5.33%
Applied Molecular TransportN/AN/AN/A

Earnings & Valuation

This table compares Schrödinger and Applied Molecular Transport's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Schrödinger$85.54 million63.99$-24,570,000.00N/AN/A
Applied Molecular TransportN/AN/A$-28,040,000.00N/AN/A

Schrödinger has higher revenue and earnings than Applied Molecular Transport.

Summary

Applied Molecular Transport beats Schrödinger on 7 of the 9 factors compared between the two stocks.

Galapagos (NASDAQ:GLPG) and Applied Molecular Transport (NASDAQ:AMTI) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Valuation & Earnings

This table compares Galapagos and Applied Molecular Transport's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galapagos$1.00 billion5.15$167.83 million$5.4614.46
Applied Molecular TransportN/AN/A$-28,040,000.00N/AN/A

Galapagos has higher revenue and earnings than Applied Molecular Transport.

Institutional and Insider Ownership

11.2% of Galapagos shares are owned by institutional investors. Comparatively, 52.0% of Applied Molecular Transport shares are owned by institutional investors. 2.9% of Galapagos shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Galapagos and Applied Molecular Transport's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Galapagos-70.67%-11.78%-5.58%
Applied Molecular TransportN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings for Galapagos and Applied Molecular Transport, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Galapagos210502.18
Applied Molecular Transport00403.00

Galapagos currently has a consensus price target of $143.7273, suggesting a potential upside of 82.05%. Applied Molecular Transport has a consensus price target of $68.75, suggesting a potential upside of 63.96%. Given Galapagos' higher probable upside, equities analysts clearly believe Galapagos is more favorable than Applied Molecular Transport.

Applied Molecular Transport (NASDAQ:AMTI) and Biohaven Pharmaceutical (NYSE:BHVN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, institutional ownership and valuation.

Analyst Ratings

This is a breakdown of recent recommendations for Applied Molecular Transport and Biohaven Pharmaceutical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Applied Molecular Transport00403.00
Biohaven Pharmaceutical021002.83

Applied Molecular Transport currently has a consensus target price of $68.75, indicating a potential upside of 63.96%. Biohaven Pharmaceutical has a consensus target price of $96.4545, indicating a potential upside of 29.37%. Given Applied Molecular Transport's stronger consensus rating and higher possible upside, equities research analysts plainly believe Applied Molecular Transport is more favorable than Biohaven Pharmaceutical.

Earnings & Valuation

This table compares Applied Molecular Transport and Biohaven Pharmaceutical's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Applied Molecular TransportN/AN/A$-28,040,000.00N/AN/A
Biohaven PharmaceuticalN/AN/A$-528,800,000.00($10.91)-6.83

Profitability

This table compares Applied Molecular Transport and Biohaven Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Applied Molecular TransportN/AN/AN/A
Biohaven PharmaceuticalN/A-1,091.41%-120.85%

Insider & Institutional Ownership

52.0% of Applied Molecular Transport shares are owned by institutional investors. Comparatively, 99.4% of Biohaven Pharmaceutical shares are owned by institutional investors. 19.1% of Biohaven Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Applied Molecular Transport beats Biohaven Pharmaceutical on 5 of the 8 factors compared between the two stocks.

Applied Molecular Transport (NASDAQ:AMTI) and Sage Therapeutics (NASDAQ:SAGE) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, risk and dividends.

Institutional and Insider Ownership

52.0% of Applied Molecular Transport shares are owned by institutional investors. 4.8% of Sage Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Applied Molecular Transport and Sage Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Applied Molecular TransportN/AN/AN/A
Sage Therapeutics-7,706.84%-63.81%-56.64%

Earnings and Valuation

This table compares Applied Molecular Transport and Sage Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Applied Molecular TransportN/AN/A$-28,040,000.00N/AN/A
Sage Therapeutics$6.87 million646.96$-680,240,000.00($13.38)-5.69

Applied Molecular Transport has higher earnings, but lower revenue than Sage Therapeutics.

Analyst Ratings

This is a summary of current ratings and recommmendations for Applied Molecular Transport and Sage Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Applied Molecular Transport00403.00
Sage Therapeutics08802.50

Applied Molecular Transport currently has a consensus price target of $68.75, indicating a potential upside of 63.96%. Sage Therapeutics has a consensus price target of $87.0625, indicating a potential upside of 14.36%. Given Applied Molecular Transport's stronger consensus rating and higher probable upside, equities analysts clearly believe Applied Molecular Transport is more favorable than Sage Therapeutics.

Summary

Applied Molecular Transport beats Sage Therapeutics on 7 of the 10 factors compared between the two stocks.


Applied Molecular Transport Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$95.95+0.9%$5.56 billion$66.51 million17.70Analyst Report
Analyst Revision
Perrigo logo
PRGO
Perrigo
2.5$41.48+0.7%$5.50 billion$4.84 billion-691.22
Schrödinger logo
SDGR
Schrödinger
1.3$78.18+0.2%$5.49 billion$85.54 million0.00Insider Selling
News Coverage
Galapagos logo
GLPG
Galapagos
1.3$78.95+0.6%$5.20 billion$1.00 billion-11.96Analyst Upgrade
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$74.56+1.7%$4.70 billionN/A-6.08Analyst Revision
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$76.13+0.8%$4.41 billion$6.87 million-7.36Unusual Options Activity
Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.06+1.1%$4.28 billion$204.89 million-36.33
I-Mab logo
IMAB
I-Mab
1.2$57.00+0.2%$4.11 billion$4.31 million-1.97Increase in Short Interest
Gap Up
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$67.08+1.4%$4.10 billion$806.43 million-9.50Analyst Report
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$76.06+2.1%$3.99 billion$1.11 billion24.46Analyst Report
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$54.28+1.4%$3.84 billion$117.91 million-11.01
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$44.83+2.6%$3.81 billionN/A0.00Analyst Report
Increase in Short Interest
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$73.74+4.7%$3.78 billionN/A-21.01Analyst Report
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.99+2.7%$3.60 billionN/A-6.20Analyst Report
Analyst Revision
News Coverage
Gap Down
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.11+1.3%$3.53 billion$114.62 million-7.71Analyst Report
Insmed logo
INSM
Insmed
1.2$32.62+3.1%$3.47 billion$136.47 million-12.55
LEGN
Legend Biotech
1.2$25.40+1.6%$3.43 billion$64.39 million0.00Decrease in Short Interest
Gap Down
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.14+0.3%$3.39 billion$339.08 million-12.29Analyst Report
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$48.96+1.6%$3.39 billion$306.98 million-7.00
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$91.07+1.2%$3.34 billion$26.52 million-8.02
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$47.37+0.5%$3.29 billion$36.13 million-70.70
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$113.23+3.6%$3.17 billionN/A-56.33Insider Selling
Alkermes logo
ALKS
Alkermes
1.2$19.65+0.6%$3.15 billion$1.17 billion-42.72
Arvinas logo
ARVN
Arvinas
1.5$62.57+0.7%$3.08 billion$42.98 million-24.44
MorphoSys logo
MOR
MorphoSys
0.3$22.75+1.9%$3.05 billion$80.43 million108.34Decrease in Short Interest
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$62.88+5.5%$2.91 billion$421.03 million22.14Analyst Report
Insider Selling
News Coverage
Gap Up
OPKO Health logo
OPK
OPKO Health
1.9$4.27+1.2%$2.89 billion$901.90 million-23.72
Organogenesis logo
ORGO
Organogenesis
1.0$21.22+6.5%$2.89 billion$260.98 million-353.67
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
0.9$75.43+1.3%$2.85 billion$644.77 million-10.76
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$10.10+2.3%$2.73 billion$182.24 million-8.78Analyst Upgrade
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$45.18+4.5%$2.72 billion$25 million-9.04Insider Selling
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$43.67+0.3%$2.71 billionN/A-23.99
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.50+2.0%$2.69 billion$306.49 million25.28
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.28+3.4%$2.62 billion$60,000.00-9.71
Xencor logo
XNCR
Xencor
1.2$42.78+4.4%$2.59 billion$156.70 million-30.56
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.88+1.1%$2.57 billion$2.11 million-8.85Analyst Report
Analyst Revision
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$33.76+3.6%$2.48 billion$15 million-17.68Unusual Options Activity
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$148.93+0.0%$2.47 billion$120.28 million-150.43Analyst Report
Decrease in Short Interest
ALX Oncology logo
ALXO
ALX Oncology
1.9$60.50+0.2%$2.42 billionN/A0.00Analyst Report
Insider Selling
Increase in Short Interest
Cryoport logo
CYRX
Cryoport
1.9$50.89+4.0%$2.41 billion$33.94 million-87.74Gap Up
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$44.96+0.2%$2.25 billion$963.01 million13.96
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$29.33+2.7%$2.18 billion$23.90 million-18.22Analyst Report
Unusual Options Activity
Gap Down
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.6$49.10+2.4%$2.06 billionN/A0.00Insider Selling
Analyst Revision
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$123.42+2.6%$2.03 billionN/A-11.15
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.07+4.0%$2.01 billion$410,000.00-5.88Analyst Report
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$25.52+2.2%$2.00 billion$103.54 million-19.19Insider Selling
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$60.11+3.8%$2.00 billionN/A-25.58Increase in Short Interest
Amarin logo
AMRN
Amarin
1.6$4.93+1.6%$1.97 billion$429.76 million-98.58Analyst Revision
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$52.15+0.9%$1.97 billionN/A-19.39
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$21.39+3.5%$1.96 billion$34.51 million-18.28Gap Down
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.